Human Genome Sciences  

(Public, NASDAQ:HGSI)   Watch this stock  
Find more results for HGSI
- Close
NASDAQ real-time data - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 2.85B
P/E     -
Div/yield     -
EPS -1.36
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin -153.79% -290.98%
Operating margin -124.61% -251.61%
EBITD margin - -236.37%
Return on average assets -28.59% -28.00%
Return on average equity -109.91% -73.14%
Employees 1,100 -
CDP Score - -


14200 Shady Grove Road
United States - Map
+1-301-3098504 (Phone)
+1-301-3098512 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company�s products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company�s internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.